Requires Adobe Acrobat ReaderRequires Adobe Acrobat Reader| Organ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Heart-Lung | Heart | Intestine | Kidney | KP | Liver | Lung | PAK | PTA | |||
| Transplants (2007) | 29 | 2,207 | 198 | 16,623 | 862 | 6,489 | 1,471 | 261 | 208 | ||
| Tx With Immunosuppression Info at Discharge | 27 | 2,135 | 194 | 16,114 | 840 | 6,207 | 1,404 | 247 | 197 | ||
| Induction Drug Reported | 81.5% | 53.9% | 49.0% | 78.0% | 78.0% | 25.8% | 62.3% | 80.2% | 67.0% | ||
| Induction Drugs | Atgam/NRATG/NRATS | 33.3% | 4.2% | 0.5% | 1.1% | 1.8% | 1.2% | 5.8% | 1.2% | 1.0% | |
| OKT3 | 7.4% | 3.2% | 17.5% | 1.2% | 1.2% | 2.9% | 1.0% | 0.4% | 7.6% | ||
| Thymoglobulin | 0.0% | 19.2% | 23.7% | 43.8% | 52.0% | 9.6% | 4.3% | 61.9% | 42.1% | ||
| Zenapax | 11.1% | 12.7% | 9.8% | 10.8% | 6.5% | 8.2% | 16.2% | 2.0% | 7.1% | ||
| Simulect | 25.9% | 14.2% | 2.1% | 16.6% | 5.7% | 5.6% | 25.9% | 4.0% | 3.6% | ||
| Campath | 18.5% | 2.6% | 13.4% | 9.5% | 13.2% | 1.4% | 9.8% | 12.1% | 13.7% | ||
| Tx With Immunosuppression Info and Functioning Graft at Discharge | 26 | 2,044 | 166 | 15,884 | 826 | 5,902 | 1,325 | 228 | 182 | ||
| Maintenance at Discharge | Corticosteroids Use | 100.0% | 88.7% | 77.1% | 65.9% | 65.4% | 75.9% | 95.3% | 58.3% | 58.2% | |
| Steroids | 100.0% | 88.7% | 77.1% | 65.9% | 65.4% | 75.9% | 95.3% | 58.3% | 58.2% | ||
| Calcineurin Inhibitor Use | 100.0% | 97.9% | 97.0% | 95.6% | 98.3% | 97.9% | 97.6% | 97.8% | 97.3% | ||
| Cyclosporine | 3.8% | 33.0% | 0.0% | 10.1% | 4.5% | 7.2% | 10.1% | 4.8% | 2.2% | ||
| Tacrolimus | 96.2% | 64.9% | 97.0% | 85.4% | 93.8% | 90.7% | 87.5% | 93.0% | 95.1% | ||
| Antimetabolite Use | 84.6% | 91.9% | 22.9% | 92.1% | 91.2% | 72.8% | 92.2% | 94.3% | 59.3% | ||
| Mycophenolate Mofetil | 65.4% | 85.6% | 21.1% | 75.0% | 73.2% | 67.2% | 54.3% | 83.8% | 52.2% | ||
| Mycophenolate Sodium | 3.8% | 3.4% | 0.0% | 16.4% | 17.2% | 4.9% | 6.4% | 9.2% | 5.5% | ||
| Azathioprine | 15.4% | 2.8% | 1.8% | 0.6% | 0.7% | 0.6% | 31.5% | 1.3% | 1.6% | ||
| Leflunomide | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||
| mTOR Inhibitor Use | 0.0% | 4.5% | 9.0% | 5.2% | 10.5% | 2.5% | 0.2% | 7.9% | 17.0% | ||
| Sirolimus | 0.0% | 1.2% | 9.0% | 4.8% | 10.5% | 2.5% | 0.2% | 7.9% | 17.0% | ||
| Everolimus | 0.0% | 3.3% | 0.0% | 0.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||
| Transplants (2006) | 31 | 2,193 | 175 | 17,091 | 924 | 6,650 | 1,406 | 293 | 173 | ||
| Tx With Maintenance Use at 1yr PostTx | 20 | 1,879 | 120 | 15,092 | 803 | 5,245 | 1,141 | 218 | 122 | ||
| Maintenance at 1yr PostTx | Corticosteroids Use | 100.0% | 68.4% | 60.8% | 65.8% | 67.6% | 39.6% | 97.4% | 67.4% | 48.4% | |
| Steroids | 100.0% | 68.4% | 60.8% | 65.8% | 67.6% | 39.6% | 97.4% | 67.4% | 48.4% | ||
| Calcineurin Inhibitor Use | 95.0% | 96.5% | 99.2% | 91.7% | 96.4% | 92.7% | 96.8% | 95.0% | 99.2% | ||
| Cyclosporine | 5.0% | 32.0% | 1.7% | 11.2% | 6.2% | 8.3% | 11.2% | 6.9% | 2.5% | ||
| Tacrolimus | 90.0% | 64.5% | 97.5% | 80.6% | 90.2% | 84.5% | 85.5% | 88.1% | 96.7% | ||
| Antimetabolite Use | 85.0% | 87.1% | 6.7% | 86.7% | 83.8% | 49.3% | 84.6% | 83.0% | 50.0% | ||
| Mycophenolate Mofetil | 60.0% | 76.7% | 5.8% | 67.7% | 57.7% | 44.1% | 51.3% | 67.4% | 35.2% | ||
| Mycophenolate Sodium | 0.0% | 5.1% | 0.0% | 16.9% | 24.4% | 4.7% | 4.6% | 13.3% | 13.9% | ||
| Azathioprine | 25.0% | 5.2% | 0.8% | 1.4% | 1.0% | 0.6% | 28.7% | 1.4% | 0.8% | ||
| Leflunomide | 0.0% | 0.2% | 0.0% | 0.8% | 0.7% | 0.0% | 0.0% | 0.9% | 0.0% | ||
| mTOR Inhibitor Use | 0.0% | 9.3% | 12.5% | 11.3% | 16.1% | 9.4% | 6.1% | 16.1% | 22.1% | ||
| Sirolimus | 0.0% | 7.6% | 12.5% | 10.8% | 16.1% | 9.4% | 6.1% | 16.1% | 22.1% | ||
| Everolimus | 0.0% | 1.6% | 0.0% | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||
Requires Adobe Acrobat Reader